{"entity": "journal", "iuid": "bf0f32f3fc67445cb7421f778c0ecadb", "timestamp": "2026-08-22T06:58:27.335Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/journal/Ann%20Surg%20Oncol.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/journal/Ann%20Surg%20Oncol"}}, "title": "Ann Surg Oncol", "issn": "1534-4681", "issn-l": null, "publications_count": 4, "publications": [{"entity": "publication", "iuid": "14b2ef2f913248088213022215d163e5", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/14b2ef2f913248088213022215d163e5.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/14b2ef2f913248088213022215d163e5"}}, "title": "ASO Author Reflections: Neoadjuvant Hepatic Arterial Infusion Chemotherapy with Oxaliplatin, Fluorouracil, and Leucovorin Is an Incredible Helper in Curing Patients with Intermediate-Advanced-Stage and Technically Resectable Hepatocellular Carcinoma.", "authors": [{"family": "Pan", "given": "Yangxun", "initials": "Y"}, {"family": "Xu", "given": "Li", "initials": "L"}], "type": "journal article", "published": "2022-03-00", "journal": {"title": "Ann Surg Oncol", "issn": "1534-4681", "volume": "29", "issue": "3", "pages": "2030-2031", "issn-l": null}, "abstract": null, "doi": "10.1245/s10434-021-11028-4", "pmid": "34739640", "labels": [], "xrefs": [{"db": "pii", "key": "10.1245/s10434-021-11028-4"}], "notes": [], "created": "2026-08-21T12:42:49.434Z", "modified": "2026-08-21T12:42:49.464Z"}, {"entity": "publication", "iuid": "15bdf0972c504343b556f8922386183f", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/15bdf0972c504343b556f8922386183f.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/15bdf0972c504343b556f8922386183f"}}, "title": "Comparison Between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate to Advanced Stage Hepatocellular Carcinoma.", "authors": [{"family": "Pan", "given": "Yangxun", "initials": "Y"}, {"family": "Mei", "given": "Jie", "initials": "J"}, {"family": "Chen", "given": "Jinbin", "initials": "J"}, {"family": "Zhang", "given": "Deyao", "initials": "D"}, {"family": "Wang", "given": "Juncheng", "initials": "J"}, {"family": "Wang", "given": "Xiaohui", "initials": "X"}, {"family": "Yi", "given": "Minjiang", "initials": "M"}, {"family": "Zhou", "given": "Zhongguo", "initials": "Z"}, {"family": "Zhang", "given": "Yaojun", "initials": "Y"}, {"family": "Chen", "given": "Minshan", "initials": "M"}, {"family": "Guo", "given": "Rongping", "initials": "R"}, {"family": "Xu", "given": "Li", "initials": "L"}], "type": "journal article", "published": "2022-03-00", "journal": {"title": "Ann Surg Oncol", "issn": "1534-4681", "volume": "29", "issue": "3", "pages": "2016-2029", "issn-l": null}, "abstract": "Patients with intermediate to advanced stage hepatocellular carcinoma (HCC; Barcelona Clinic Liver Cancer [BCLC] stage B/C) have few choices of curable treatments and thus suffer from dismal outcomes. Although surgical resection could prolong survival in certain selected patients with BCLC stage B/C HCC, the frequent postoperative recurrence and poor survival of these patients need to be improved by combining other therapies perioperatively.\n\nThis study was conducted to investigate the survival associations of adjuvant portal vein perfusion chemotherapy (PVC) and neoadjuvant hepatic arterial infusion chemotherapy (HAIC) in patients with resectable BCLC stage B/C HCC.\n\nA retrospective study was conducted in consecutive patients who underwent R0 resection for intermediate to advanced stage HCC, combined with either PVC or HAIC perioperatively between January 2017 and December 2018. Patients treated with PVC or HAIC were analyzed according to intention-to-treat (ITT) and per protocol (PP) principles, respectively. The chemotherapy regimen of adjuvant PVC and neoadjuvant HAIC included 5-fluorouracil/leucovorin/oxaliplatin. Survival analysis and Cox regression for overall survival (OS) and event-free survival (EFS) were used to compare the outcomes.\n\nAmong all 64 patients enrolled in this study, 28 received perioperative PVC and 36 received HAIC for ITT analysis. Age (median 44.00 vs. 46.50 years; p = 0.364), sex (male: 25/28 vs. 35/36; p = 0.435), and tumor size (median 9.55 vs. 8.10 cm; p = 0.178) were comparable between the two groups. In the ITT analysis, the median OS was significantly longer in patients in the HAIC group compared with the PVC group (median OS not reached vs. 19.47 months; p = 0.004); in the PP analysis, patients who received neoadjuvant HAIC followed by hepatectomy presented with much better EFS than patients in the PVC group (modified EFS 16.90 vs. 3.17 months; p = 0.022); and in the multivariate analysis, neoadjuvant HAIC presented as a significant predictor for enhanced EFS (hazard ratio [HR] 0.296; p = 0.007) and OS (HR 0.095; p = 0.007) for BCLC stage B/C HCC patients who received hepatectomy.\n\nCompared with adjuvant PVC, neoadjuvant HAIC treatment was associated with better survival and fewer recurrences in HCC patients who received R0 resection at the intermediate to advanced stage. These results need to be further validated prospectively.", "doi": "10.1245/s10434-021-10903-4", "pmid": "34637058", "labels": [], "xrefs": [{"db": "pii", "key": "10.1245/s10434-021-10903-4"}], "notes": [], "created": "2026-08-21T12:42:45.465Z", "modified": "2026-08-21T12:42:45.493Z"}, {"entity": "publication", "iuid": "acc91502f011449fa044438b8dd8672e", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/acc91502f011449fa044438b8dd8672e.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/acc91502f011449fa044438b8dd8672e"}}, "title": "ASO Visual Abstract: Comparison between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate/Advanced-Stage Hepatocellular Carcinoma", "authors": [{"family": "Pan", "given": "Yangxun", "initials": "Y"}, {"family": "Mei", "given": "Jie", "initials": "J"}, {"family": "Chen", "given": "Jinbin", "initials": "J"}, {"family": "Zhang", "given": "Deyao", "initials": "D"}, {"family": "Wang", "given": "Juncheng", "initials": "J"}, {"family": "Wang", "given": "Xiaohui", "initials": "X"}, {"family": "Yi", "given": "Minjiang", "initials": "M"}, {"family": "Zhou", "given": "Zhongguo", "initials": "Z"}, {"family": "Zhang", "given": "Yaojun", "initials": "Y"}, {"family": "Chen", "given": "Minshan", "initials": "M"}, {"family": "Guo", "given": "Rongping", "initials": "R"}, {"family": "Xu", "given": "Li", "initials": "L"}], "type": "journal-article", "published": "2022-03-00", "journal": {"title": "Ann Surg Oncol", "issn": "1534-4681", "volume": "29", "issue": "3", "pages": "2032-2033", "issn-l": null}, "abstract": null, "doi": "10.1245/s10434-021-10970-7", "pmid": null, "labels": [], "xrefs": [], "notes": [], "created": "2026-08-21T12:42:47.611Z", "modified": "2026-08-21T12:42:47.631Z"}, {"entity": "publication", "iuid": "df98a5ee276f481f938c5d5f8df94c12", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/df98a5ee276f481f938c5d5f8df94c12.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/df98a5ee276f481f938c5d5f8df94c12"}}, "title": "Gains of Chromosome 1p and 15q are Associated with Poor Survival After Cytoreductive Surgery and HIPEC for Treating Colorectal Peritoneal Metastases.", "authors": [{"family": "Enblad", "given": "Malin", "initials": "M", "orcid": "0000-0001-5900-0900", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/bd2f8ad89196420584d0f79ad24575d3.json"}}, {"family": "Graf", "given": "Wilhelm", "initials": "W"}, {"family": "Terman", "given": "Alexei", "initials": "A"}, {"family": "Pucholt", "given": "Pascal", "initials": "P"}, {"family": "Viklund", "given": "Bj\u00f6rn", "initials": "B"}, {"family": "Isaksson", "given": "Anders", "initials": "A"}, {"family": "Birgisson", "given": "Helgi", "initials": "H"}], "type": "journal article", "published": "2019-12-00", "journal": {"title": "Ann Surg Oncol", "issn": "1534-4681", "volume": "26", "issue": "13", "pages": "4835-4842", "issn-l": null}, "abstract": "Genetic alterations in colorectal peritoneal metastases (PM) are largely unknown. This study was designed to analyze whole-genome copy number alterations (CNA) in colorectal PM and to identify alterations associated with prognosis after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).\n\nAll patients with PM, originating from a colorectal adenocarcinoma, who were treated with CRS and HIPEC in Uppsala Sweden, between 2004 and 2015, were included (n = 114). DNA derived from formalin-fixed paraffin-embedded (FFPE) specimens were analyzed for CNA using molecular inversion probe arrays.\n\nThere were extensive but varying degrees of CNA, ranging from minimal CNA to total aneuploidy. In particular, gain of parts of chromosome 1p and major parts of 15q were associated with poor survival. A combination of gains of 1p and 15q was associated with poor survival, also after adjustment for differences in peritoneal cancer index and completeness of cytoreduction score [hazard ratio (HR) 5.96; 95% confidence interval (CI) 2.19-16.18]. These patients had a mean copy number (CN) of 3.19 compared with 2.24 in patients without gains. Complete CN analysis was performed in 53 patients. Analysis was unsuccessful for the remaining patients due to insufficient amounts of DNA and signals caused by interstitial components and normal cells. There was no difference in survival between patients with successful and unsuccessful CN analysis.\n\nThis study shows that gains of parts of chromosome 1p and of major parts of chromosome 15q were significantly associated with poor survival after CRS and HIPEC, which could represent future prognostic biomarkers.", "doi": "10.1245/s10434-019-07923-6", "pmid": "31620944", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC6863794"}, {"db": "pii", "key": "10.1245/s10434-019-07923-6"}], "notes": [], "created": "2026-08-21T12:42:43.101Z", "modified": "2026-08-21T12:42:43.169Z"}], "created": "2026-08-21T12:42:43.132Z", "modified": "2026-08-21T12:42:43.132Z"}